Pfizer’s Biohaven Bet Pays Off Again as Migraine Nasal Spray Wins Approval 3/10/2023
Clinical Hold on Fulcrum's Sickle Cell Hopeful Triggered by Hematologic Malignancies Profile 3/10/2023
Independent Panel Recommends Polivy in First Line LBCL Despite FDA Reservations 3/10/2023
Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data 3/9/2023
Bayer Plans to Double Down on US Pharma R&D in 2023 3/9/2023
AstraZeneca Notches Back-to-Back Late-Stage Wins in Lung Cancer 3/9/2023
How ChatGPT Can–and Can't–Help Your Job Search 3/9/2023
QurAlis’ Biomarker-Driven Approach Attracts $88M in Series B 3/9/2023
Lilly’s Alzheimer’s Struggles Continue as Preclinical Disease Asset Fails Phase III 3/9/2023
Closing the Opportunity Gap: How Inceptor Bio Supports Women Leaders 3/9/2023
In Tough Market, CODA Quietly Shuts Doors 3/8/2023
BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia 3/8/2023
FDA Accepts Mesoblast’s Ryoncil Resubmission for Pediatric GVHD 3/8/2023
Co-working could Drive Innovation, Distribution of Talent Across U.S. 3/8/2023
The Decade of RNA Delivery – Beyond the Liver 3/8/2023
Rapport Therapeutics Snags $100M for Precision Approach to Neurological Diseases 3/7/2023
Moderna Eyes Accelerated Approval for mRNA Cancer Vaccine 3/7/2023
Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor 3/7/2023
Merck Preps Potential First Oral PCSK9 Inhibitor for Phase III 3/7/2023
Small Study of BridgeBio's Dwarfism Drug Indicates Advantage over BioMarin 3/7/2023